Statement Coil embolization for the treatment of peripheral veins: A position statement of the International Union of Phlebology (UIP), the Australasian College of Phlebology (ACP), the Australia and New Zealand Society for Vascular Surgery (ANZSVS), the American Venous Forum (AVF), the American Vein and Lymphatic Society (AVLS), and the Interventional Radiology Society of Australia (IRSA) Kurosh Parsi 1,2 , Andrew Hill 3 , Andrew Bradbury 1 , Mark Meissner 1,4,5 , Antonios Gasparis 4 , Christopher Rogan 2,6 and Andre van Rij 2 The following statement has been published on behalf of International Union of Phlebology (UIP), American Venous Forum (AVF), American Vein and Lymphatic Society (AVLS), Australasian College of Phlebology (ACP), Australia and New Zealand Society for Vascular Surgery (ANZSVS) and Interventional Radiology Society of Australasia (IRSA). The contribution has been co-published in Phlebology [DOI: 10.1177/0268355520908156] and Journal of Vascular Surgery: Venous and Lymphatic Disorders [DOI: 10.1016/j.jvsv.2020.02.013]. The publications are identical except for minor stylistic and spelling differences in keeping with each journal’s style. The contri- bution has been published under a Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), (https://creativecommons.org/licenses/by-nc-nd/4.0/). Beneficial treatment options for incompetent saphe- nous veins, including endovenous thermal ablation, ultrasound-guided foam sclerotherapy and traditional surgery have been established by rigorous randomized clinical trials and recommended by several internation- al evidence-based guidelines. 1–4 There is currently no high-quality evidence to support the use of physical embolic agents, a such as coils, to treat axial venous reflux. Accordingly, we recommend against the use of such approaches for the treatment of saphenous incom- petence outside of the clinical trial settings (Grade 2C against, Table 1). Note a. This statement applies to physical embolic agents only, and not applicable to cyanoacrylate adhesives and other liquid embolic agents. References 1. National Institute for Health and Care Excellence. CG168 varicose veins in the legs: the diagnosis and management of varicose veins. Manchester: NICE, 2013. 2. Gloviczki P, Comerota AJ, Dalsing MC, et al. The care of patients with varicose veins and associated chronic venous diseases: clinical practice guidelines of the Society for Vascular Surgery and the American Venous Forum. J Vasc Surg 2011; 53: 2S–48S. 3. Gloviczki P and Gloviczki ML. Guidelines for the man- agement of varicose veins. Phlebology 2012; 27: 2–9. 4. Wittens C, Davies AH, Baekgaard N, et al. Editor’s choice – management of chronic venous disease: clinical practice guidelines of the European Society for vascular surgery (ESVS). Eur J Vasc Endovasc Surg 2015 Jun; 49 (6): 678–737. 1 International Union of Phlebology (UIP) 2 Australasian College of Phlebology (ACP) 3 Australia and New Zealand Society for Vascular Surgery (ANZSVS) 4 American Venous Forum (AVF) 5 American Vein and Lymphatic Society (AVLS) 6 Interventional Radiology Society of Australia (IRSA) Phlebology 0(0) 1–2 ! The Author(s) 2020 Article reuse guidelines: sagepub.com/journals-permissions DOI: 10.1177/0268355520908156 journals.sagepub.com/home/phl